Alnylam and BridgeBio are competing for people who are switching from Pfizer’s blockbuster ATTR amyloidosis drug tafamidis while all three companies are fighting for new patients.

Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been approved by the Food and Drug Administration (FDA) to treat transthyretin amyloid cardiomyopathy (ATTR-CM), a potentially fatal disease of the ...

In one study, Alnylam Pharmaceuticals' Amvuttra helped lower the risk of death and heart problems by 28% over three years compared to a placebo. The drug is given as a shot every three months.

A program called Alnylam Assist may also be available. »Learn more about saving on your prescriptions. If you’d like to explore an alternative to Amvuttra, talk with your doctor. They can ...

The increased compensation for Greenstreet comes after a big 2024 for the Cambridge drugmaker during which Alnylam laid out promising Phase 3 data for the drug Amvuttra in a rare heart disease ...

Analysts' ratings for Alnylam Pharmaceuticals ALNY over the last quarter vary from bullish to bearish, as provided by 27 analysts. The following table summarizes their recent ratings, shedding light ...

said in a news release by Alnylam, the maker of Amvuttra. "The availability of this groundbreaking treatment option is a significant moment for patients living with ATTR amyloidosis. It ...

The analyst likes the strategic market position of the company, which has been boosted by the recent approval of Amvuttra to treat ATTR-CM. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) had a ...

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated ...

Federal officials have approved Alnylam's new heart drug, Amvuttra The treatment lowered risk of death and heart issues by 28% in one study It costs roughly $476,000 a year MONDAY, March 24 ...

Alnylam Pharmaceuticals, Inc.’s ALNY share price has dipped by 10.08%, which has investors questioning if this is right time to buy.

The drug, called Amvuttra (vutrisiran), is made by Alnylam Pharmaceuticals Inc. and is used to treat transthyretin amyloid cardiomyopathy. ATTR-CM is a disease in which harmful proteins build up ...